Trending Now
- “All the evidence is on my desk. Each piece of evidence will be revealed at the right time.” – CM Vijay
- “The TVK Govt will fall into the abyss as quickly as it came to power.” – EPS
- “Anbumani undertook several marches with slogans such as ‘Save the Palar’, ‘Save the Vaigai’, ‘Save the Thamirabarani’, and ‘Save the Noyyal’.” – PMK legislative party leader Sowmiya Anbumani
- “After killing three Tamils, how can Karnataka CM Shivakumar speak so arrogantly? I condemn the Karnataka Govt’s attitude.” – Seeman
- CM Vijay announces increase in Health Insurance coverage from Rs.5 lakh to Rs.25 lakh annually under rule 110 in the Assembly.
- “Claims that Vijay will be the next PM should not be taken seriously.” – Manickam Tagore, President, TN Congress Committee
Coimbatore
Invesco Mutual Fund launches the ‘Invesco India Pharma and Healthcare Fund’.
August 19, 2026
Coimbatore, August 19 : Invesco Mutual Fund announced the launch of Invesco India Pharma and Healthcare Fund (An open ended equity scheme investing in Pharma, Healthcare and allied sectors). The fund seeks to capitalize on India’s evolving healthcare ecosystem, which is being shaped by favourable demographics, expanding healthcare access, rising insurance penetration, growing global pharmaceutical leadership, and emerging innovation-driven opportunities across healthcare and life sciences. The scheme will invest across pharmaceutical companies, hospitals, diagnostics, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), medical devices, healthcare services, insurance and other allied healthcare segments. The fund will be managed by Aditya Khemani and will be benchmarked against the BSE Healthcare TRI. Speaking at the launch, Aditya Khemani, Head of Equity & Fund Manager, Invesco Mutual Fund, said “India’s healthcare sector is undergoing a structural transformation. The country is not only witnessing rising healthcare consumption driven by favourable demographics and increasing affordability but is also strengthening its position as a global pharmaceutical and healthcare innovation hub. We see attractive opportunities across domestic pharma, hospitals, diagnostics, CDMOs and emerging healthcare segments that can potentially benefit from this multi-year growth cycle. Our investment approach will focus on identifying quality businesses with sustainable competitive advantages and strong growth visibility across the healthcare ecosystem.”The minimum lumpsum investment amount during the NFO is ₹1,000/- and in multiples of ₹1/- thereafter. For SIP investments, the minimum application amount is ₹100/- and in multiples of ₹1/- thereafter. The fund will charge an exit load of 0.50% for units redeemed/switched out on or before 3 months from the date of allotment. No exit load will be charged if units are redeemed/switched out after 3 months. The New Fund Offer (NFO) is open for subscription from today (August 18, 2026) and will close on September 1, 2026.
